Encapsulation of Andrographolide in poly(lactide-co-glycolide) Nanoparticles: Formulation Optimization and in vitro Efficacy Studies.

Autor:	Oseni BA; Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria.; Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, United States., Azubuike CP; Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria., Okubanjo OO; Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria., Igwilo CI; Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, Lagos, Nigeria., Panyam J; Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, United States.; School of Pharmacy, Temple University, Philadelphia, PA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2021 Feb 18; Vol. 9, pp. 639409. Date of Electronic Publication: 2021 Feb 18 (Print Publication: 2021).
DOI:	10.3389/fbioe.2021.639409
Abstrakt:	Andrographolide is a potential chemopreventive and chemotherapeutic agent that suffers from poor aqueous solubility. Encapsulation in poly(lactide-co-glycolide) (PLGA) nanoparticles can overcome solubility issues and enable sustained release of the drug, resulting in improved therapeutic efficacy. In this study, andrographolide was encapsulated in PLGA nanoparticles via emulsion solvent evaporation technique. Effect of various formulation parameters including polymer composition, polymer molecular weight, polymer to drug ratio, surfactant concentration and the organic solvent used on nanoparticle properties were investigated. A selected formulation was used to determine the effect of encapsulation in nanoparticles on andrographolide's in vitro anticancer efficacy. Nanoparticles formulated using a polymer with 85:15 lactide to glycolide ratio and ethyl acetate as the organic solvent were found to be optimal based on average hydrodynamic particle size (135 ± 4 nm) and drug loading (2.6 ± 0.6%w/w). This formulation demonstrated sustained release of andrographolide over 48 h and demonstrated significantly greater in vitro anticancer efficacy compared to free drug in a metastatic breast cancer cell line. These results suggest that additional, more in-depth efficacy studies are warranted for the nanoparticle formulation of andrographolide. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Oseni, Azubuike, Okubanjo, Igwilo and Panyam.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu